Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of ...

In this study, we identify ATRX, a chromatin remodeler of the SWI/SNF family, as a new binding protein of the cohesin complex. ATRX directly interacts with the cohesin accessory subunit Pds5B, ...

Long-term outcomes in GIST Trial 13-162: Phase II study of imatinib in combination with binimetinib in untreated patients with advanced gastrointestinal stromal tumor (GIST). This is an ASCO Meeting ...

Compare To: ATRX Compare Select to analyze similar companies using key performance metrics; select up to 4 stocks. ATRX Adhera Therapeutics, Inc. 0.0001 0.00% Mkt cap 722 Industry Biotechnology SEELQ ...

SEC Filings provided by EDGAR Online, Inc.

Tumor proportion score (TPS) and response to first-line (1L) anti–PD-1/PD-L1 plus chemotherapy for metastatic non-small cell lung cancer (NSCLC): A real-world cohort study. Retrospective ...